Ok so the final email to be sent to Tom -...

Ok so the final email to be sent to Tom - [email protected]
Who would like to do the honors?

-------------------------------------

Hi Tom,

Hope you are well.

Ive had discussions with a group of investors and instead of bombarding you with questions of a similar nature we have decided to compile a list of questions from all of us for you to hopefully assist us with (we will post the answers on Hotcopper so all investors a part of forming this list get their answers satisfied).

Questions:

About Announcement

1. Why would you give notice of a conference call within 30 minutes of the conference call commencing? Why not announce something like that on Friday?

2. Why didn’t Dr Baldwin or Loveridge participate in the conference? When will we get a chance to be able to ask them questions directly?

About Drug

3. If Presendin has been dropped, what protection against off-label use of generics does Invex have?
Is it only orphan drug designation?

4. Can you contrast the expected PK for Peptron's sustained Exenatide vs. Byetta vs. Daily Presendin or Exenatide vs. Bydureon vs. Daily Presendin


5. Why is Invex comfortable in proceeding straight to a P3 without repeating the P2 with Peptron's formulation?

6. What exactly has been licensed in/out and to whom (i.e., by how much have we cut potential profits globally by using Peptron's SR-formulation); for what cost (whether it be financial or otherwise); what are the limitations to each party during and post P3.

7. What has the FDA/EMA seen of PT320? Have they seen any of the pharmacokinetics or tolerability studies? Is the data package ready to go or will it need to be generated? How confident is Invex that the regulators would deem the current preclinical studies for PT320 to be acceptable?

8. Do you think that the preclinical and clinical data from Peptron about PT320 will change the FDA's mind on the recommended primary endpoint for the phase III trial for Presendin?

9. What superior aspects does PT320 have over Bydureon apart from the faster steady state?

10. Is IXC going to be using a unique formulation of exenatide for IIH treatment? If not then our sale potential must surely decrease if we are just relying on orphan drug designation

11. Many other ASX listed companies publish the list of members on their Scientific Advisory Board. Can Invex release a list of members on their scientific advisory board?

12. Are management/directors now able to purchase shares on market considering the collaboration deal is over. If yes, will we be seeing purchasing to instill further confidence to shareholders of how undervalued this company is?

13. What are the next steps for IXC at the moment. What are they focusing on the most at this current stage and whose working in what areas?

Appreciate your time Tom and looking forward to hearing your answers to the above.

Thanks

Kind regards,